Adalbert Krawczyk1, Christian Hintze2, Jessica Ackermann1, Birgit Goitowski1, Martin Trippler3, Nico Grüner1, Maria Neumann-Fraune4, Jens Verheyen5, Melanie Fiedler6. 1. Institute of Virology, University Hospital Essen, University Duisburg-Essen, Hufelandstr. 55, 45122 Essen, Germany. 2. DiaSorin Deutschland GmbH, Von-Hevesy-Str. 3, 63128 Dietzenbach, Germany. 3. Department of Gastroenterology and Hepatology, University Hospital Essen, University Duisburg-Essen, Hufelandstr. 55, 45122 Essen, Germany. 4. Institute of Virology, University of Cologne, Fürst-Pückler-Str. 56, 50935 Köln, Germany. 5. Institute of Virology, University Hospital Essen, University Duisburg-Essen, Hufelandstr. 55, 45122 Essen, Germany; Institute of Virology, University of Cologne, Fürst-Pückler-Str. 56, 50935 Köln, Germany. 6. Institute of Virology, University Hospital Essen, University Duisburg-Essen, Hufelandstr. 55, 45122 Essen, Germany. Electronic address: melanie.fiedler@uni-due.de.
Abstract
BACKGROUND: The fully automated and closed LIAISON(®)XL platform was developed for reliable detection of infection markers like hepatitis B virus (HBV) surface antigen (HBsAg), hepatitis C virus (HCV) antibodies (Ab) or human immunodeficiency virus (HIV)-Ag/Ab. To date, less is known about the diagnostic performance of this system in direct comparison to the common Abbott ARCHITECT(®) platform. OBJECTIVES: We compared the diagnostic performance and usability of the DiaSorin LIAISON(®)XL with the commonly used Abbott ARCHITECT(®) system. STUDY DESIGN: The qualitative performance of the above mentioned assays was compared in about 500 sera. Quantitative tests were performed for HBsAg-positive samples from patients under therapy (n=289) and in vitro expressed mutants (n=37). For HCV-Ab, a total number of 155 selected samples from patients chronically infected with different HCV genotypes were tested. RESULTS: The concordance between both systems was 99.4% for HBsAg, 98.81% for HCV-Ab, and 99.6% for HIV-Ab/Ag. The quantitative LIAISON(®)XL murex HBsAg assay detected all mutants in comparable amounts to the HBsAg wild type and yielded highly reliable HBsAg kinetics in patients treated with antiviral drugs. Dilution experiments using the 2nd International Standard for HBsAg (WHO) showed a high accuracy of this test. HCV-Ab from patients infected with genotypes 1-3 were equally detected in both systems. Interestingly, S/CO levels of HCV-Ab from patients infected with genotype 3 seem to be relatively low using both systems. CONCLUSIONS: The LIAISON(®)XL platform proved to be an excellent system for diagnostics of HBV, HCV, and HIV with equal performance compared to the ARCHITECT(®) system.
BACKGROUND: The fully automated and closed LIAISON(®)XL platform was developed for reliable detection of infection markers like hepatitis B virus (HBV) surface antigen (HBsAg), hepatitis C virus (HCV) antibodies (Ab) or human immunodeficiency virus (HIV)-Ag/Ab. To date, less is known about the diagnostic performance of this system in direct comparison to the common Abbott ARCHITECT(®) platform. OBJECTIVES: We compared the diagnostic performance and usability of the DiaSorin LIAISON(®)XL with the commonly used Abbott ARCHITECT(®) system. STUDY DESIGN: The qualitative performance of the above mentioned assays was compared in about 500 sera. Quantitative tests were performed for HBsAg-positive samples from patients under therapy (n=289) and in vitro expressed mutants (n=37). For HCV-Ab, a total number of 155 selected samples from patients chronically infected with different HCV genotypes were tested. RESULTS: The concordance between both systems was 99.4% for HBsAg, 98.81% for HCV-Ab, and 99.6% for HIV-Ab/Ag. The quantitative LIAISON(®)XL murex HBsAg assay detected all mutants in comparable amounts to the HBsAg wild type and yielded highly reliable HBsAg kinetics in patients treated with antiviral drugs. Dilution experiments using the 2nd International Standard for HBsAg (WHO) showed a high accuracy of this test. HCV-Ab from patients infected with genotypes 1-3 were equally detected in both systems. Interestingly, S/CO levels of HCV-Ab from patients infected with genotype 3 seem to be relatively low using both systems. CONCLUSIONS: The LIAISON(®)XL platform proved to be an excellent system for diagnostics of HBV, HCV, and HIV with equal performance compared to the ARCHITECT(®) system.
Authors: Ahmad Farooq; Usman Waheed; Hasan Abbas Zaheer; Fahad Aldakheel; Shatha Alduraywish; Muhammad Arshad Journal: PLoS One Date: 2017-11-22 Impact factor: 3.240
Authors: Seung Gyu Yun; Jin Woo Jang; Jong Han Lee; Chae Seung Lim; Jinhong Kim; Yeona Ki; Minjoung Jo; Soyoun Kim Journal: Biomed Res Int Date: 2015-09-17 Impact factor: 3.411
Authors: Francisca Sosa-Jurado; Daniel Meléndez-Mena; Nora H Rosas-Murrieta; Belinda Guzmán-Flores; Miguel A Mendoza-Torres; Roberto Barcenas-Villalobos; Luis Márquez-Domínguez; Paulina Cortés-Hernández; Julio Reyes-Leyva; Verónica Vallejo-Ruiz; Gerardo Santos-López Journal: PLoS One Date: 2018-10-10 Impact factor: 3.240